<div class="entities" style="line-height: 2.5; direction: ltr">Admission Date:  [**2189-9-13**]              Discharge Date:   [**2189-10-8**]<br><br>Date of Birth:  [**2144-11-9**]             Sex:   F<br><br>Service: MEDICINE<br><br>Allergies:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Ciprofloxacin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Zomig
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>Attending:[**First Name3 (LF) 11040**]<br>Chief Complaint:<br>
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Altered
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mental
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    status
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
<br><br>Major Surgical or Invasive Procedure:<br>Arterial Line<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Mechanical
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Ventilation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>PICC placement<br><br>History of Present Illness:<br>44yo 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    autoimmune
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and transplant presented for AMS at<br>[**Hospital1 **] senior healthcare at [**Location (un) **]. Finger stick was 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    50
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 so<br>got 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    D50
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, was 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    combative
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    screaming
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 in ED so got 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    haldol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
,<br>tried NGT and desatted so decided to intubate for airway<br>protection given degree of AMS. Then got 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lactulose
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 by 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NGT
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
, got<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CTX
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2g
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Vanc
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1g
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
. Nothing tapable on bedside U/S. CT abdomen no<br>acute process, no significant 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ascites
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  Got head CT which was<br>negative. Got limited portal doppler stud which was unchanged<br>from prior w/ known 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. No family present so<br>far.<br>.<br>In the ED, initial vs were: T  P 106 BP 90/54 R 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 sat 100% CMV<br>TV 550, 14, PEEP 5 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    FiO2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 100%.  UOP 1400cc since foley placed<br>which was around 9 hours ago.<br><br><br>Past Medical History:<br>- 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Autoimmune
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, s/p orthotopic liver transplant in UAB<br>in 2/98, known 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chronic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rejection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and now with recurrence,<br>complicated by 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>- 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Chronic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>- Chronic 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphedema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, which developed after her liver transplant<br>- 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Psorasis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>- 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Allergic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rhinitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>- Dysfunctional 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    uterine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 s/p partial hysterectomy<br>- s/p 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CCY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>- 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Depression
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>- Adnexal masses noted on scan in [**12/2187**]<br>- 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Antiphospholipid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibody
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>- Staph epidermatis 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bactermia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 [**5-/2189**]<br><br>Social History:<br>- Lives with daughter and grandson<br>- [**Name (NI) 1139**]: Denies<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    etOH
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: Rarely<br>- Illicits: Denies<br><br><br>Family History:<br>- Several relatives with heart disease and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>- No history of auto-immune hepatitis or liver failure<br><br>Physical Exam:<br>General: Jaundiced woman, in restraints. Moves all extremities<br>spontaneously but does not follow commands. Does not open eyes<br>to command.<br>HEENT: 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Scleral
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    icterus
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, MMM, oropharynx clear<br>Neck: supple, JVP not elevated, no LAD<br>Lungs: Clear to auscultation anteriorly, no wheezes, rales,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ronchi
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>CV: Regular rate and rhythm, normal S1 + S2, no murmurs, rubs,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    gallops
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>Abdomen: soft, non-tender, non-distended, bowel sounds present,<br>no rebound tenderness or guarding, no organomegaly<br>GU: foley present with dark urine<br>Ext: 3+ 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    total
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 body 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anasarca
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br><br>Pertinent Results:<br>Admission labs:<br>[**2189-9-13**] 02:42PM   TYPE-ART TEMP-37.8 TIDAL VOL-528 PEEP-5 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-40<br>PO2-166* PCO2-29* PH-7.34* TOTAL CO2-16* BASE XS--8<br>INTUBATED-INTUBATED<br>[**2189-9-13**] 02:42PM   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LACTATE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-2.4*<br>[**2189-9-13**] 02:42PM   freeCa-1.09*<br>[**2189-9-13**] 02:22PM 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    URINE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
  HOURS-RANDOM<br>[**2189-9-13**] 09:55AM   TYPE-ART TEMP-36.4 TIDAL VOL-610 PEEP-5 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-40<br>PO2-136* PCO2-28* PH-7.33* TOTAL CO2-15* BASE XS--9 -ASSIST/CON<br>INTUBATED-INTUBATED<br>[**2189-9-13**] 09:55AM   freeCa-1.09*<br>[**2189-9-13**] 05:17AM   freeCa-1.00*<br>[**2189-9-13**] 03:52AM   CALCIUM-7.1* PHOSPHATE-3.8 MAGNESIUM-1.5*<br>[**2189-9-13**] 03:52AM   WBC-12.7* RBC-3.11* HGB-10.4* HCT-32.0*<br>MCV-103* MCH-33.5* MCHC-32.6 RDW-17.2*<br>[**2189-9-12**] 05:33PM   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LACTATE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-3.3*<br>[**2189-9-12**] 04:33PM 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    URINE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
  BLOOD-SM NITRITE-POS PROTEIN-NEG<br>GLUCOSE-NEG KETONE-NEG 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BILIRUBIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-NEG UROBILNGN-NEG PH-5.0<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LEUK
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>[**2189-9-12**] 03:47PM   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LACTATE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-5.5*<br>[**2189-9-12**] 03:42PM   ALT(SGPT)-44* AST(SGOT)-81* TOT BILI-6.3*<br>[**2189-9-12**] 03:42PM   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMMONIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
155*<br>[**2189-9-12**] 03:42PM   NEUTS-85.9* LYMPHS-7.4* MONOS-5.9 EOS-0.3<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BASOS
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-0.6<br>[**2189-9-12**] 03:42PM   PT-19.7* PTT-41.4* INR(PT)-1.8*<br><br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    MICRO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 (Many other studies other than those listed below were<br>negative)<br>-[**9-12**] 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    UCx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ESCHERICHIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 COLI. &gt;100,000 ORGANISMS/ML. ESBL.<br>         SENSITIVE TO 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tigecycline
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 &lt;=1MCG/ML.<br>         RESISTANT TO 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    MEROPENEM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 &lt;=1MCG/ML.<br>         RESISTANT TO 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IMIPENEM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 &lt;=1MCG/ML.<br>                             |<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMIKACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------   &lt;=2 S<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------  =&gt;32 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SULBACTAM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--  =&gt;32 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFAZOLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-------------  =&gt;64 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFEPIME
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFTAZIDIME
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-----------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFTRIAXONE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-----------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CIPROFLOXACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
---------   =&gt;4 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GENTAMICIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------  =&gt;16 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IMIPENEM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    MEROPENEM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-------------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NITROFURANTOIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------    32 S<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PIPERACILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TAZO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
----- =&gt;128 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TETRACYCLINE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
----------   &lt;=4 S<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TOBRAMYCIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------     8 I<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TRIMETHOPRIM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SULFA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
----  =&gt;16 R<br><br>-[**9-13**] 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    UCx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: GRAM NEGATIVE ROD(S). ~4000/ML<br>-[**9-20**] 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Mycolytic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BCx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
: BLOOD/FUNGAL CULTURE (Preliminary):    NO<br>FUNGUS ISOLATED. BLOOD/AFB CULTURE (Preliminary):    NO<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    MYCOBACTERIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 ISOLATED.<br>-[**9-28**] BAL: GRAM STAIN: 1+ (&lt;1 per 1000X FIELD):<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    POLYMORPHONUCLEAR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LEUKOCYTES
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. NO MICROORGANISMS SEEN.<br>   RESPIRATORY CULTURE: Commensal Respiratory Flora Absent.<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    YEAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    100
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ML
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.<br>   LEGIONELLA CULTURE (Final [**2189-10-5**]):    NO LEGIONELLA<br>ISOLATED.<br>   
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    FUNGAL
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary): YEAST.    OF TWO COLONIAL<br>MORPHOLOGIES.<br>   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 FAST SMEAR (Final [**2189-9-29**]): NO AFB SEEN ON CONCENTRATED<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SMEAR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 FAST CULTURE (Preliminary):    NO MYCOBACTERIA ISOLATED.<br>-[**9-28**] Rapid Viral Screen/Culture: No respiratory viruses<br>isolated. No Cytomegalovirus (CMV) isolated. +HERPES SIMPLEX<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    VIRUS
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TYPE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 1. CONFIRMED BY MONOCLONAL FLUORESCENT ANTIBODY<br>-[**9-30**] 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    UCx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: YEAST &gt;100,000 ORGANISMS/ML<br>-[**10-5**] 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BCx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: GRAM NEGATIVE ROD(S).    PRELIMINARY SENSITIVITY.<br>                             
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GRAM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NEGATIVE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 ROD(S)<br>                             |<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMIKACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------       S<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SULBACTAM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CIPROFLOXACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
---------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GENTAMICIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PIPERACILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TAZO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-----       R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TOBRAMYCIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------       R<br>-[**10-5**] BAL:   GRAM STAIN (Final [**2189-10-5**]):<br>      3+  (5-10 per 1000X FIELD):   POLYMORPHONUCLEAR<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LEUKOCYTES
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>      1+    (&lt;1 per 1000X FIELD):   GRAM NEGATIVE ROD(S).<br>      1+    (&lt;1 per 1000X FIELD):   BUDDING YEAST.<br>   MODIFIED 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    FAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 STAIN FOR 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NOCARDIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: Test cancelled by<br>laboratory due to lack of branching gram positive rods in the<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    gram
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>   RESPIRATORY CULTURE (Preliminary):<br>      10,000-100,000 ORGANISMS/ML. Commensal Respiratory Flora.<br>      
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ESCHERICHIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    COLI
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.    10,000-100,000 ORGANISMS/ML..<br>      
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    YEAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.    ~ ~3000/ML.<br>                             
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ESCHERICHIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    COLI
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>                             |<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMIKACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------   &lt;=2 S<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------  =&gt;32 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AMPICILLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SULBACTAM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--  =&gt;32 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFAZOLIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-------------  =&gt;64 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFEPIME
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
--------------       PND<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFTAZIDIME
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-----------  =&gt;64 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CEFTRIAXONE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-----------  =&gt;64 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CIPROFLOXACIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
---------   =&gt;4 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GENTAMICIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------  =&gt;16 R<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    MEROPENEM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-------------       PND<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TOBRAMYCIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
------------     8 I<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TRIMETHOPRIM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SULFA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
----  =&gt;16 R<br>   LEGIONELLA 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary):    NO LEGIONELLA ISOLATED.<br>   POTASSIUM 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HYDROXIDE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 PREPARATION (Final [**2189-10-6**]): Test<br>cancelled by laboratory.<br>   
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    FUNGAL
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary):    NO FUNGUS ISOLATED.<br>   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 FAST SMEAR (Final [**2189-10-6**]): NO AFB SEEN ON CONCENTRATED<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SMEAR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    FAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary):<br>   
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NOCARDIA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary):<br>   
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    VIRAL
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CULTURE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (Preliminary):    No Virus isolated so far<br><br>STUDIES:<br>-[**9-12**] ECG: Baseline artifact. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Sinus
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Early<br>precordial 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    R
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    wave
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    progression
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Compared to the previous tracing<br>of [**2189-8-27**] the 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    sinus
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 rate is much faster. The other findings are<br>similar.<br><br>-[**9-12**] CXR: No gross pulmonary process noted. If clinically<br>feasible, consider repeat study once patient is able to tolerate<br>the procedure.<br><br>-[**9-12**] CT Abd/Pelvis: 1. No acute intra-abdominal or pelvic<br>process to explain the patient's symptoms.<br>  2. Status post 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    orthotopic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    liver
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    transplant
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with diffuse<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anasarca
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Known<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombus
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 is not well evaluated on the current study.<br><br>  3. Trace pleural 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and minimal atelectasis.<br>  4. Unchanged 8 mm left 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>-[**9-12**] CT Head 1. Stable appearance of the brain without evidence<br>of an acute 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intracranial
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abnormality
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
.<br>2. The partially imaged orogastric tube appears to make a loop<br>in the<br>nasopharynx.<br><br>-[**9-12**] Abdominal U/S: Limited study as above with persistent main<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and no evidence of intrahepatic portal<br>vein flow, similar to [**2189-8-27**].<br><br>-[**9-21**] Renal U/S: 8-mm left renal calculus within the lower<br>pole, unchanged from CT scan of [**2189-9-12**]. No evidence of<br>hydronephrosis or obstruction.<br><br>-[**9-23**] CT Chest/Abd/Pelvis: 1. Bilateral, multifocal<br>consolidative 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    airspace
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    opacities
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. These have progressed compared<br>to recent chest radiographs, and are new compared to [**2189-9-12**] CT of the abdomen and pelvis (when the lung bases were<br>imaged). This most likely represents 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    multifocal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>Aspiration and a component of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pulmonary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 could also be<br>considered. Clinical correlation is advised.<br>2. Malpositioned left upper extremity PICC, with tip extending<br>into the right ventricle. This should be withdrawn for optimal<br>positioning.<br>3. Findings compatible with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>4. Large pulmonary artery compatible with pulmonary<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>5. Status post 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    liver
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    transplantation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. There is small ascites and<br>diffuse<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anasarca
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, a distended IVC, and mild cardiomegaly, all compatible<br>with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fluid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    overload
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>6. 11-mm non-obstructing left 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>7. No retroperitoneal hematoma or other source of blood loss, as<br>questioned.<br><br>-[**9-23**] CT Head: 1. Study limited by motion shows no large<br>intracranial 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hemorrhage
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 or other obvious acute intracranial<br>abnormality.<br>  2. Persistent catheter fragment seen to course from one side<br>of nasal cavity to the other on prior CT of [**2189-9-12**]; clinical<br>correlation recommended.<br><br>-[**9-26**] RUQ U/S: Limited evaluation with the main portal vein<br>again not<br>visualized. However, flow appears present in the left hepatic<br>vein and left hepatic artery. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ascites
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>-[**9-27**] Abd X-ray: No evidence for obstruction; NG tube in place.<br><br>Brief Hospital Course:<br>The patient was initially admitted to MICU [**Location (un) **] for severe<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 requiring intubation in the ED for airway<br>protection. She was treated for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, with<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lactulose
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rifaximin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Initial cultures revealed<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    carbapenemase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    resistant
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    E
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    .
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coli
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, for which she was initially<br>treated with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nitrofurantoin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    amikacin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Nitrofurantoin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was<br>subsequently discontinued. Per ID recommendations, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>were changed to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    colistin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, then ultimately to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tetracycline
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. She<br>was weaned off of the ventilator and was transferred to the<br>internal medicine service on [**9-16**]. Her 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lactulose
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 dose was<br>increased. Her renal function worsened, which was believed<br>likely due to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nephrotoxic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    medications
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
. She was also started on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    octreotride
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    midodrine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    albumin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatorenal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    syndrome
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Se<br>was transferred back to MICU Green on [**9-19**] for worsening<br>encephalopathy and labs consistent with low-grade 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DIC
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, including<br>a ten point 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematocrit
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    drop
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombocytopenia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, worsening<br>coagulation studies, and indirect hyperbilirubinemia. Hematology<br>was consulted and agreed with diagnosis of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DIC
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Over the<br>subsequent days, the patient required large amounts of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>products, including 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    red
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cells
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    platelets
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cryoprecipitate
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
,<br>and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fresh
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    frozen
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    plasma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
. Despite these measures, she still had<br>large amounts of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bloody
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    output
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 from her rectal tube; she was<br>felt too unstable to undergo any GI procedures, and was treated<br>with further 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    transfusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
. Her significant 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypernatremia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypercalcemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 improved to some degree during her stay in the<br>MICU. The patient's mental status did not improve, and she was<br>reintubated for hypoxic 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    respiratory
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
, which was partially<br>due to a new 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Her mental status was sufficiently poor<br>that she only required intermittent 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    sedation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 for her<br>endotracheal tube. She had high residuals through her OG tube,<br>and tube feeds frequently had to be held. She had frequent<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bloody
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    secretions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 from her endotracheal tube; bronchoscopy<br>revealed diffuse oozing of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 throughout her bronchi.<br>Multiple family meetings were held, including a meeting with the<br>patient's primary hepatologist, who confirmed that the patient<br>was not a candidate for retransplantation. As the patient's<br>liver disease was believed to be a central factor in her<br>deteriorating condition, measures were transitioned towards<br>making the patient comfortable and prolonging her life only long<br>enough for her family members to be able to say goodbye. She<br>passed away peacefully with her family at her side.<br><br>Medications on Admission:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lactulose
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    30cc
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Atovaquone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    750
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    5
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mL
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10cc
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Citalopram
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    20
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Montelukast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Mycophenolate
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Mofetil
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    500
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 [**Hospital1 **]<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Omeprazole
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    20
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifaximin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    550
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 [**Hospital1 **]<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Spironolactone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    50mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Prednisone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Sucralfate
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    gram
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    QID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tacrolimus
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    0
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    .
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    5
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Torsemide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    15
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Calcium
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    600
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    with
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Vitamin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    D3
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    600
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ,
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    500mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    400
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    unit
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    twice
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 a<br>day.<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Ursodiol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    600
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br><br><br>Discharge Medications:<br>Deceased<br><br>Discharge Disposition:<br>Expired<br><br>Discharge Diagnosis:<br>Primary:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Disseminated
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intravascular
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coagulation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hepatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Fulminant
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Urinary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tract
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hypernatremia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hypercalcemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
<br><br>Secondary:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Autoimmune
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, s/p orthotopic liver transplant in [**2176**]<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Chronic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    portal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>Chronic 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphedema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, which developed after her liver transplant<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Psorasis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Allergic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rhinitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Dysfunctional
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    uterine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 s/p partial hysterectomy<br>s/p 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cholecystectomy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Depression
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>Adnexal masses noted on scan in [**12/2187**]<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Antiphospholipid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibody
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br>Discharge Condition:<br>Deceased<br><br>Discharge Instructions:<br>Deceased<br><br>Followup Instructions:<br>Deceased<br><br><br></div>